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Recent work shows that TRAILshort, a membrane-bound short form of TRAIL, is 
expressed by human cancer cells and protects them from TRAIL-induced cell death. A 
monoclonal antibody that selectively targets TRAILshort enhances cancer susceptibility 
to TRAIL and increases the efficacy of autologous CD8+T cells in ex vivo primary 
tumours. 
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In this issue of Clinical Cancer Research, Aboulnasr and colleagues  (1), in an elegant 
well controlled study, provide new experimental evidences that may partly explain the 
intrinsic resistance of cancer cells to TRAIL and the low efficacy of TRAIL in cancer 
treatment: a great proportion of human cancers express and secrete a shorter form of 
TRAIL, TRAILshort, that does not show cytotoxic potential but competes with the 
binding of TRAIL to its two receptors TRAIL-R1 and R2, impeding the activation of 
TRAIL-induced cell death pathways in cancer cells. 
TRAIL activates cell death and/or survival pathways upon binding to two specific 
receptors in humans TRAIL-R1/DR4) and TRAIL-R2/DR5. In addition, it possesses 
two non-functional decoy receptors, DcR1 and DcR2. The ability to induce cell death 
together with the low toxicity against healthy tissue/cells aimed several clinical trials to 
test its efficacy against different cancers alone or in combination with other molecules. 
However, the original promising results employing animal models (2) were not 
translated into human patients and the results of the clinical trials were disappointing as 
they did not reveal any significant benefit of TRAIL in disease progression and outcome 
(3). Indeed, different studies showed that most cancer cell lines as well as primary 
patient-derived cells were resistant to TRAIL in vitro. In addition, the contribution of 
TRAIL to CD8+ cytotoxic T cell-mediated cell death is not clear yet. 
Aboulnasr et al identify RNA transcripts for TRAILshort in 40% of human cancers in 
two data bases (Gene Expression Omnibus (GEO) and the Atlas of Human Cancer), of 
which 15% expressed high/very high levels. These results were subsequently validated 
at the protein level by IHC in tissues from different cancer types and its functional 
relevance tested in vitro and in vivo employing a new humanized antibody that 
selectively binds TRAILshort but not the long active form of TRAIL. The authors found 
that several human cancer cell lines from different origin as well as primary lymphoma 
cells were more sensitive to TRAIL-induced apoptosis in the presence of the anti-
TRAILshort antibody in vitro. A similar result was also found in xenograft mouse 
models (NSG) in vivo employing two hematological cell lines, albeit in this case the 
results were modest. Meritoriously, authors employ an ex vivo autologous human model 
of lymphoma to show that anti-TRAILshort antibody enhances autologous CD8+T cells-
mediated elimination of lymphoma cells, suggesting that TRAIL is used by CD8+T cells 
to kill cancer cells, a question that is not clear yet.  
TRAILshort, firstly identified in HIV-infected patients produced by alternative splicing, 
lacks exons 3 and 4 resulting in the appearance of an unique C-terminal 11 aminoacid 
sequence followed by a premature stop codon in exon 5 (4). TRAILshort lacks the 
typical TNF-homology domain, which causes the loss of the Cysteine 230, which is 
responsible for stabilizing the trimeric conformation of full-length TRAIL, impeding the 
homo-trimerisation of TRAILshort and accounting for its monomeric nature. 
Interestingly, in contrast to full-length TRAIL that can also be found in a soluble form 
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due to cleavage by a putative metalloprotease, TRAILshort could only be detected in a 
non-cleaved form and associated with microvesicles/exosomes. Noteworthy, full length 
TRAIL was also shown to be released associated to exosomes by CD8+T cells (3), 
which implies that TRAILshort, in addition to blocking soluble TRAIL and anti-
TRAIL-R agonistic antibodies, is also able to block the exosome-bound full length 
TRAIL. Regarding tumour spatial heterogeneity, expression and secretion of 
TRAILshort in exosomes by a few number of cancer cell clones in specific tumour sites 
might benefit the expansion of distal clones that do not express it, promoting a 
community immunoevasion mechanism. These are important questions for designing 
future clinical trials combining immune checkpoint inhibitors (ICIs) with anti-
TRAILshort antibodies.  
Expression of TRAILshort provides an additional explanation to the low efficacy of 
TRAIL in the elimination of cancer cells in vitro and in vivo, and to the disappointing 
clinical trial results using TRAIL or agonistic anti-TRAIL-R1/2 antibodies. Importantly, 
only those cancer types that express TRAILshort respond to the anti-TRAILshort 
antibody, reinforcing the validity of the conclusions and advancing a potential 
biomarker to predict those tumors that will most benefit of this potential therapy. 
Besides inducing cell death, TRAIL can also activate proliferative/pro-survival 
pathways such as NF-kB. Thus, it will be important to study if TRAILshort, in contrast 
to cell death activation, can still activate these pathways. If so, blocking TRAILshort 
would not only enhance susceptibility to TRAIL-induced cell death but, in addition, 
would directly impact tumour proliferation/survival. 
Previous studies have shown a role for the TRAIL pathway in cancer 
immunosurveillance (5). Intriguingly, the contribution of TRAIL to the elimination of 
cancer cells by mature NK or cytotoxic CD8+ T cells is very low in comparison with 
other effector molecules like perforin and granzymes or even Fas Ligand. This low 
activity has been attributed to the expression of intracellular molecules that regulate the 
extrinsic apoptotic pathway like FLIP, members of the IAP family or even the decoy 
receptors DcR1 and DcR2. However, the relevance of all of them for TRAIL 
immunosurveillance and immunotherapy is unclear. Now, TRAILshort emerges as a 
novel contributor to cancer immunoevasion and a potential target to enhance TRAIL 
antitumoral effect (Figure). This finding suggests that TRAILshort blockade might 
synergize with granule exocytosis (perforin and granzymes) to enhance cancer cell 
killing, albeit this hypothesis will require further experimental validation. Blocking 
TRAILshort enhances the anti-tumoral action of CD8+T cells, which prompts us to 
speculate on a potential synergy with ICIs against PD1/L1, TIM3 and/or LAG3. It will 
also be interesting to analyse the effect of anti-TRAILshort antibodies on NK cell 
mediated-immunosurveillance and immunotherapy (i.e. by combining anti-TRAILshort 
with antibodies against NK cell checkpoints like NKG2A or with antibodies with 
ADCC activity) since TRAIL is also a component of the cytotoxic machinery of NK 
cells.  
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Expression of TRAILshort seems to be highly dependent on activation of certain pro-
inflammatory pathways, such as Type I interferon and TLR activation. In this line, in 
contrast to HIV patients, where both infected and non-infected cells expressed 
TRAILshort and were protected from TRAIL-induced cell death (4), expression of 
TRAILshort in cancer patients was exclusively found in cancer cells. Thus, selective 
activation of certain inflammatory signaling pathways in cancer cells would lead to 
TRAILshort expression and acquired TRAIL-resistance. This hypothesis will require 
further experimental validation in future studies to better understand the specific 
settings where TRAILshort might be expressed and design more efficient protocols 
employing anti-TRAILshort antibodies. The preliminary data presented by Aboulnasr 
and collaborators show that blocking of TRAILshort did not increase the sensitivity of 
non-activated PBLs to TRAIL. Activated PBLs were not included in the analyses, 
which might be important considering the role of type I IFN in the regulation of 
TRAILshort expression. TRAIL has shown a very good safety profile in several studies 
and clinical trials, with very few adverse effects (3). Nonetheless, in light of the results 
presented here, the potential toxicity (including immune-related adverse effects) of anti-
TRAILshort antibodies alone or in combination with TRAIL receptor agonists will 
require careful analyses in animal models before clinical trials employing these 
combinations can be proposed.  
The discovery of a new mechanism/function is always exciting, especially when it helps 
to explain previous negative results of molecules already tested at the clinical level, 
providing new ways to improve their efficacy. Obviously, it raises many new questions 
aimed at better understanding the biological significance of the new findings and the 
opportunities to use this knowledge for the clinical benefit of cancer patients. Thus, the 
present study by Andrew Badley’s lab opens a lot of questions, but most importantly it 
contributes to understand the role of TRAIL during the elimination of cancer cells by 
effector CD8+T cells, and provides a potential new target to increase the efficacy of 
TRAIL-based treatments for cancer. 
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TRAILshort counteracts cell death induced by TRAIL. Tumour cells express a short 
form of TRAIL, TRAILshort that is secreted bound to exosomes. TRAILshort binds to 
TRAIL-R1 and 2, DR4 and DR5, but does not show cytotoxic potential. Contrary it 
competes with the binding of TRAIL to DR4 and DR5, impeding the activation of cell 
death pathways in cancer cells by TRAIL-expressing cytotoxic CD8+T cell or by 
treatments like recombinant TRAIL or agonistic anti-DR antibodies. A monoclonal 
antibody that selectively binds to TRAILshort prevents binding of TRAILshort to DR4 
and DR5 and enhances the susceptibility of cancer cells to TRAIL-expressing cytotoxic 
CD8+T cells or TRAIL-based treatments. 
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